Vertex Pharmaceuticals Inc / Ma financial data

Symbol
VRTX on Nasdaq
Location
50 Northern Avenue, Boston, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 4, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 254 % -18.1%
Quick Ratio 35.7 % +49.5%
Debt-to-equity 39.9 % +18.1%
Return On Assets 15.6 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 254M shares -1.48%
Common Stock, Shares, Outstanding 254M shares -1.47%
Entity Public Float 122B USD +34.3%
Common Stock, Value, Issued 2.5M USD -3.85%
Weighted Average Number of Shares Outstanding, Basic 256M shares -0.93%
Weighted Average Number of Shares Outstanding, Diluted 258M shares -1.3%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 11.7B USD +10.3%
Costs and Expenses 7.73B USD -29.1%
Operating Income (Loss) 3.99B USD +6.26%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 4.45B USD +1614%
Income Tax Expense (Benefit) 774M USD +4.63%
Net Income (Loss) Attributable to Parent 3.68B USD +3.59%
Earnings Per Share, Basic 14 USD/shares +4.69%
Earnings Per Share, Diluted 14 USD/shares +4.74%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.94B USD -5.72%
Marketable Securities, Current 1.35B USD +4.83%
Accounts Receivable, after Allowance for Credit Loss, Current 1.95B USD +11.2%
Inventory, Net 1.63B USD +50.7%
Other Assets, Current 76.4M USD -9.37%
Assets, Current 10.6B USD +7.81%
Deferred Income Tax Assets, Net 2.94B USD +27.2%
Operating Lease, Right-of-Use Asset 1.59B USD +14%
Intangible Assets, Net (Excluding Goodwill) 430M USD -48.3%
Goodwill 1.09B USD 0%
Other Assets, Noncurrent 1.1B USD +10.9%
Assets 24.9B USD +11.8%
Accounts Payable, Current 420M USD +6.19%
Employee-related Liabilities, Current 352M USD +19.4%
Accrued Liabilities, Current 3.61B USD +12.2%
Liabilities, Current 4.48B USD +12.6%
Operating Lease, Liability, Noncurrent 1.83B USD +15.5%
Other Liabilities, Noncurrent 1.23B USD +32.2%
Liabilities 7.54B USD +14.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax -64.5M USD -324%
Retained Earnings (Accumulated Deficit) 12.4B USD +42.3%
Stockholders' Equity Attributable to Parent 17.3B USD +10.8%
Liabilities and Equity 24.9B USD +11.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 819M USD -37.3%
Net Cash Provided by (Used in) Financing Activities -680M USD -90.3%
Net Cash Provided by (Used in) Investing Activities -55.8M USD +97.4%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 254M shares -1.47%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 113M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4.95B USD -5.72%
Interest Paid, Excluding Capitalized Interest, Operating Activities 2.7M USD -73%
Deferred Tax Assets, Valuation Allowance 273M USD +2.36%
Deferred Tax Assets, Gross 3.16B USD +29.8%
Operating Lease, Liability 1.63B USD +327%
Payments to Acquire Property, Plant, and Equipment 40.7M USD -40.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3.58B USD +6.45%
Lessee, Operating Lease, Liability, to be Paid 2.74B USD +528%
Operating Lease, Liability, Current 87.1M USD +163%
Lessee, Operating Lease, Liability, to be Paid, Year Two 159M USD +283%
Lessee, Operating Lease, Liability, to be Paid, Year One 167M USD +297%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure +82.6%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 909M USD +1570%
Lessee, Operating Lease, Liability, to be Paid, Year Three 158M USD +291%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1M shares 0%
Unrecognized Tax Benefits 706M USD +14.7%
Lessee, Operating Lease, Liability, to be Paid, Year Four 155M USD +324%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 201M USD +1.5%
Deferred Tax Assets, Net of Valuation Allowance 2.89B USD +33.2%
Share-based Payment Arrangement, Expense 696M USD -5.84%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%